OBJECTIVE: To compare the occurrence of normal visual field (VF) test results following 2 vs 3 consecutive, abnormal, reliable test results in the Ocular Hypertension Treatment Study. METHODS: The Ocular Hypertension Treatment Study is a prospective, multicenter follow-up study as part of a longitudinal randomized clinical trial. Sixty-four (68 eyes) of 1636 participants developed a VF primary open-angle glaucoma (POAG) end point. We compared the proportion of normal VF test results after a VF POAG end point among eyes whose VF abnormality was confirmed by 2 (n = 9 eyes) vs 3 (n = 59 eyes) consecutive, abnormal, reliable VF test results. RESULTS: The proportion of VF test results that were normal subsequent to a VF POAG end point in eyes whose abnormality was confirmed by 2 consecutive, abnormal, reliable test results was significantly higher (73 [66%] of 110) compared with eyes whose abnormality was confirmed by 3 consecutive, abnormal, reliable test results (46 [12%] of 381) (P = .01). CONCLUSIONS: A VF POAG end point confirmed by 3 consecutive, abnormal, reliable VF test results appears to have greater specificity and stability than either 1 or 2 consecutive, abnormal, reliable VF test results. However, some eyes whose VF POAG end point was confirmed by 3 consecutive, abnormal, reliable test results nonetheless had 1 or more normal test results on follow-up.
RCT Entities:
OBJECTIVE: To compare the occurrence of normal visual field (VF) test results following 2 vs 3 consecutive, abnormal, reliable test results in the Ocular Hypertension Treatment Study. METHODS: The Ocular Hypertension Treatment Study is a prospective, multicenter follow-up study as part of a longitudinal randomized clinical trial. Sixty-four (68 eyes) of 1636 participants developed a VF primary open-angle glaucoma (POAG) end point. We compared the proportion of normal VF test results after a VF POAG end point among eyes whose VF abnormality was confirmed by 2 (n = 9 eyes) vs 3 (n = 59 eyes) consecutive, abnormal, reliable VF test results. RESULTS: The proportion of VF test results that were normal subsequent to a VF POAG end point in eyes whose abnormality was confirmed by 2 consecutive, abnormal, reliable test results was significantly higher (73 [66%] of 110) compared with eyes whose abnormality was confirmed by 3 consecutive, abnormal, reliable test results (46 [12%] of 381) (P = .01). CONCLUSIONS: A VF POAG end point confirmed by 3 consecutive, abnormal, reliable VF test results appears to have greater specificity and stability than either 1 or 2 consecutive, abnormal, reliable VF test results. However, some eyes whose VF POAG end point was confirmed by 3 consecutive, abnormal, reliable test results nonetheless had 1 or more normal test results on follow-up.
Authors: Lyne Racette; Jeffrey M Liebmann; Christopher A Girkin; Linda M Zangwill; Sonia Jain; Lida M Becerra; Felipe A Medeiros; Christopher Bowd; Robert N Weinreb; Catherine Boden; Pamela A Sample Journal: Arch Ophthalmol Date: 2010-05
Authors: Hana L Takusagawa; Liang Liu; Kelly N Ma; Yali Jia; Simon S Gao; Miao Zhang; Beth Edmunds; Mansi Parikh; Shandiz Tehrani; John C Morrison; David Huang Journal: Ophthalmology Date: 2017-07-01 Impact factor: 12.079
Authors: Lyne Racette; Felipe A Medeiros; Linda M Zangwill; Diana Ng; Robert N Weinreb; Pamela A Sample Journal: Invest Ophthalmol Vis Sci Date: 2008-03 Impact factor: 4.799
Authors: Felipe A Medeiros; Renato Lisboa; Linda M Zangwill; Jeffrey M Liebmann; Christopher A Girkin; Christopher Bowd; Robert N Weinreb Journal: Ophthalmology Date: 2013-08-12 Impact factor: 12.079
Authors: Zhichao Wu; Denis S D Weng; Rashmi Rajshekhar; Robert Ritch; Donald C Hood Journal: Transl Vis Sci Technol Date: 2018-07-18 Impact factor: 3.283